New industry regulations bring with them increased costs, which lowers the R&D productivity of the entire industry. It is faster and more efficient to acquire an innovative therapeutic than to develop it in-house, but that requires a sharp focus on searching out and evaluating new candidates for mergers and acquisitions – and then negotiating the best deal that’s a win-win for everyone!
DGE’s Biopharma BD&L Summit provides an unequaled in-depth examination of partnership strategies, licensing priorities, and ways to avoid everything that can go wrong with your next big merger. With the pandemic slowing down R&D, innovative deal structures can help your team still come out on top – so don’t miss out on this unique learning and networking opportunity, presented via a proven interactive online platform.
- Strategic and tactical considerations for negotiating a term sheet
- Proven approaches for maximizing IP due diligence
- Insight on new paradigms for external innovation
- Critical evaluation methods for small companies to deploy on large companies
- New insights on how the reimbursement environment impacts the deal-making landscape
- Business Development
- Corporate Development
- Licensing
- Legal / IP
- Mergers & Acquisitions
- Strategic Alliances / Alliance Management
- Portfolio / Life Cycle Management
- Due Diligence
- Search and Evaluation
- External Innovation
- Clinical Operations
- Regulatory Affairs
- Compliance
- Scientific Assessment
- Transactions
- Private equity firms
- Investment banks
- Venture capitalists
- Law firms
- Data room providers
- Compliance specialists
- Regulatory affairs specialists
- Due diligence consultants
Stay up to date on the latest announcements